When Anat, a 42-year-old teacher in Tel Aviv, volunteered for a clinical trial testing a nasal spray for early cognitive decline, no one asked what day of her cycle she was on. That oversight—common in medical research—might have masked the very signal scientists were hunting. A groundbreaking study led by Professor Illana Gozes at Tel Aviv University now reveals that estrogen levels in female mice dictate how much of the brain-protective drug davunetide reaches the brain after nasal administration. The finding doesn’t just challenge how we run drug trials—it suggests we’ve been missing real effects by averaging across sexes and ignoring hormonal rhythms.
Davunetide, or NAP, is a synthetic snippet of a protein the brain uses to stabilize microtubules—tiny railways inside neurons that transport vital cargo. When these structures collapse, as they do in Alzheimer’s and other tauopathies, cognition falters. The drug showed promise in animal models, but in a large human trial for progressive supranuclear palsy, it failed. The average result said it didn’t work. But Gozes’ team saw something else: when they reanalyzed the data by sex, women appeared to respond. That whisper of an effect led them to track the drug in real time.
Using fluorescent tagging and live imaging, the researchers followed davunetide’s journey in mice. They imaged five animals at a time across 2.5 hours, meticulously tracking each female’s estrous cycle via vaginal smears. The results were striking: during proestrus and estrus—when estrogen peaks—female mice absorbed significantly more of the drug into their heads. In proestrus, the difference in head uptake between males and females had a p-value of 0.00029; the head-to-body ratio diverged even more sharply, at p = 0.000004. When estrogen dropped in metestrus, the gap vanished. Hormonal state wasn’t noise—it was the signal.
Even in a mixed group of 10 mice (five males, five females), unsorted by cycle phase, females still showed higher brain uptake at every time point, with a head-to-body ratio difference at p = 0.000009. The body’s circulation didn’t reflect what reached the brain—a crucial distinction for neuroactive drugs. The team then turned to human data from a prior pharmacokinetic study: two men and six women. Though small, the dataset echoed the mouse findings. Women trended toward double the peak concentration of men, while men retained the drug longer—half-life differences reaching significance at p = 0.0057.
This isn’t just about one drug. It’s about how we design trials. If estrogen opens a window for brain delivery, then timing could be everything. As Gozes puts it, “We may have been throwing out the baby with the bathwater by averaging across sexes and cycles.” The next generation of neurological therapies might not just be targeted to the brain—but to the phase of the month.